StephenTillesMD
Allergy & Immunology • Seattle, WAAsthma & Allergic Conditions
Partner, Northwest Asthma and Allergy Center; Executive Director,ASTHMA Inc. Clinical research Center
Dr. Tilles is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1959 NE Pacific St.
Seattle, WA 98195Phone+1 206-598-4615
Education & Training
University of Colorado School of Medicine/National Jewish Health (Adult)Fellowship, Allergy and Immunology, 1993 - 1995
Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 1990 - 1993
University of California San Diego School of MedicineClass of 1990
Certifications & Licensure
CA State Medical License 1992 - Present
OR State Medical License 1991 - Present
WA State Medical License 2000 - 2025
CO State Medical License 1994 - 1995- American Board of Allergy and Immunology Allergy & Immunology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Super Doctor SuperDoctors.com
- Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology
Clinical Trials
- Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma. Start of enrollment: 2002 Sep 01
- Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma Start of enrollment: 2012 Oct 01
- Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy Start of enrollment: 2015 Mar 03
- Join now to see all
Publications & Presentations
PubMed
- HLA-DRregulatory T cells and IL-10 are associated with success or failure of desensitization outcomes.Xiaoying Zhou, Diane Dunham, Sayantani B Sindher, Andrew Long, Andrea Fernandes
Allergy. 2024-09-18 - 27 citationsEffects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial.Jonathan Corren, David Larson, Matthew C Altman, R Max Segnitz, Pedro C Avila
The Journal of Allergy and Clinical Immunology. 2023-01-01 - 3 citationsEight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice.Jay Portnoy, Christina E Ciaccio, Janet Beausoleil, George Du Toit, Stanley Fineman
Allergy, Asthma, and Clinical Immunology. 2022-05-09
Journal Articles
- Foreword Drug Hypersensitivity: Broadening HorizonsStephen Tilles, MD, ScienceDirect
Press Mentions
Aimmune Presents New Clinical Data from Pooled Safety Analysis in Patients Treated with PALFORZIA® for up to ~3.5 YearsFebruary 25th, 2021- Peanut Allergy Treatment 'In Sight'November 18th, 2019
Aimmune Therapeutics Discusses AR101’S Cost-Effectiveness and Demonstrated Clinical Benefits at ICER MeetingJune 11th, 2019- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
